How do you approach a patient with recurrent VTE who develops VTE again after reduction of apixaban to 2.5 mg bid?
2
2 Answers
Mednet Member
Pulmonology · University of Kentucky Medical Center
Several factors play into this decision for me.
- Is the patient obese? Obese patients tend to give me pause for dose-reduction of DOACs. As such, half-dose apixaban may have been relatively underdosed for an obese patient and I would not call it DOAC failure, rather I would increase the dose to usua...